On March 24, 2026, Paysign, Inc. (NASDAQ: PAYS) announced its financial results for the fiscal year ended December 31, 2025, showcasing a remarkable 40.5% increase in total revenues, reaching $82.0 million compared to $58.4 million in 2024. This growth was driven by a significant expansion in patient affordability programs, which saw a staggering 167.8% increase in pharma revenue, totaling $33.9 million. The company also reported a net income of $7.55 million, or $0.13 per diluted share, nearly doubling from $3.82 million, or $0.07 per diluted share, in the previous year. Adjusted EBITDA surged by 107.3% to $19.94 million, reflecting the company's operational efficiency and strategic focus on high-margin services. Paysign's strong balance sheet, with $21.07 million in unrestricted cash and zero debt, positions it well for continued investment in growth initiatives. The company anticipates revenue growth of 30% to 35% in 2026, further solidifying its role as a leader in patient affordability solutions within the life sciences sector. The results indicate a robust operational execution and a positive outlook for the future, reinforcing investor confidence.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.